Merck KGaA Completes Millipore Acquisition and Launches New Merck Millipore Division
Merck Chemicals now comprises two new divisions: Merck Millipore and Performance Materials
Merck KGaA announced the successful completion of its acquisition of Millipore Corporation, a leading life science company based in Billerica, Massachusetts, USA, for an aggregate purchase price including debt and cash of approximately EUR 5.2 billion (US$ 7.0 billion). Merck agreed to acquire Millipore on February 28, 2010 for US$107 in cash per share of Millipore common stock. The closing follows the approval of the acquisition by Millipore’s shareholders at a special meeting held on June 3, 2010 and the satisfaction of other customary conditions, including antitrust clearance in the United States and Europe.
Merck will now begin the process of de-listing the shares of Millipore from the New York Stock Exchange and removing the shares from registration with the U.S. Securities and Exchange Commission.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Lab901 and Biofortuna to collaborate on automated PCR Dx for HLA and Coeliac disease
Asterion Raises £355k Funding to Progress Novel Therapies for Hormone Related Diseases
Evogene and Zeraim Gedera Salt Tolerant Tomato Collaboration Advances to Second Phase
Heptares granted patents covering stabilised receptor technology in Europe and Japan - Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery
Pevion’s therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity
Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics
Amarin corporation Appoints Colin W. Stewart as President and Chief Executive Officer
Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness
Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”
Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration
